136 related articles for article (PubMed ID: 35403154)
1. Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Kuwahara C
Cancer Diagn Progn; 2021; 1(5):491-498. PubMed ID: 35403154
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib.
Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Clin Endocrinol (Oxf); 2020 Jan; 92(1):71-76. PubMed ID: 31663136
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
Cheng L; Fu H; Jin Y; Sa R; Chen L
Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
5. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
6. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
[No Abstract] [Full Text] [Related]
7. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
Feng G; Luo Y; Zhang Q; Zeng F; Xu J; Zhu J
Endocrine; 2020 Apr; 68(1):56-63. PubMed ID: 31955344
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib.
Ha Y; Mohamed Ali MA; Petersen MM; Harmsen WS; Therneau TM; Lee HC; Ryoo BY; Bampoh S; Valles KA; Mady M; Missula VR; Prasai K; Roberts LR; Kim KM
Hepatol Int; 2020 Sep; 14(5):776-787. PubMed ID: 32740886
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
10. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
[TBL] [Abstract][Full Text] [Related]
12. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
13. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population.
Benekli M; Yalcin S; Ozkan M; Elkiran ET; Sevinc A; Cabuk D; Coskun HS; Oksuzoglu B; Bayar B; Akbulat A; Ozet A
Onco Targets Ther; 2015; 8():1-5. PubMed ID: 25548522
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
17. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.
Kim MJ; Kim SM; Lee EK; Hwangbo Y; Lee YJ; Cho SW; Park DJ; Lee Y; Park YJ
Endocr J; 2019 Jul; 66(7):597-604. PubMed ID: 31006722
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.
Lin ZX; Ruan DY; Li Y; Wu DH; Ma XK; Chen J; Chen ZH; Li X; Wang TT; Lin Q; Wen JY; Wu XY
World J Gastroenterol; 2015 Oct; 21(38):10898-906. PubMed ID: 26478681
[TBL] [Abstract][Full Text] [Related]
20. Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients.
Ahn J; Song E; Oh HS; Song DE; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Jun; 29(6):824-829. PubMed ID: 30864902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
